Announced Mon, 16 Mar · 20:00 IST

Vivro Financial Services Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Public Announcement for the attention of the Public Shareholders of Rekvina Laboratories Ltd ....

Listed Co AcquisitionOpen Offer TriggeredStrategic Transactions View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+4.0%1-day move
₹30.37
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+4.0+6.1+8.2+10.3+12.5+16.7+31.3+42.0+28.0+20.9
Up moveDown movePending
AI summary

Rekvina Laboratories Ltd (BSE: 526075) has received a Public Announcement for an Open Offer under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The offer is triggered by Rekvina's acquisition of 100% equity in Radiant Parenterals Limited via a Share Exchange and Purchase Agreement (SEPA) dated March 16, 2026, executed through a preferential issue of 46,27,750 equity shares at Rs 100/- per share, aggregating to Rs 4.62 crore. The Open Offer is for up to 28,90,100 equity shares (26% of the expanded share capital) at Rs 10/- per share, payable in cash, with total consideration of Rs 2.89 crore assuming full acceptance. The acquirers are Surbhit Mukesh Shah and Amit Mukesh Shah (existing promoters) along with Dhruvalkumar Patel, who will join the promoter group post-transaction. Vivro Financial Services is the Manager to the Offer.

Likely market impact

Public shareholders of Rekvina Laboratories can tender their shares in the Open Offer at Rs 10/- per share in cash. The open offer price is notably lower than the Rs 100/- preferential issue price paid to existing shareholders of Radiant Parenterals, which may limit tendering interest. Shareholders should review the Detailed Public Statement (DPS) expected within 5 working days for full terms, financial arrangements, and conditions.